Patent intelligence · CA
CA 3144557
LIGANDS D'ANTIGENE MEMBRANAIRE SPECIFIQUE DE LA PROSTATE (PSMA) ET LEURS UTILISATIONS
LIGANDS D'ANTIGENE MEMBRANAIRE SPECIFIQUE DE LA PROSTATE (PSMA) ET LEURS UTILISATIONS
Patent details — CA 3144557
- Jurisdiction
- CA
- Status
- granted
- Grant date
- Jan 7, 2021
- Expiration
- Jan 2, 2041
- CPC classes
- A61K 51/ 04 A I, A61K/510402, A61K/510482, A61K/510497
Quick answer
CA 3144557 (LIGANDS D'ANTIGENE MEMBRANAIRE SPECIFIQUE DE LA PROSTATE (PSMA) ET LEURS UTILISATIONS) is held by ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT]. Status: granted. Granted Jan 7, 2021. Expires Jan 2, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 51/ 04 A I, A61K/510402, A61K/510482, A61K/510497, A61P 35/ 00 A I, A61P/3500
More from ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT]
Related pharmaceutical patents in our USPTO index.
-
EP 4541380
STABILE KONZENTRIERTE RADIONUKLID-KOMPLEX-LÖSUNGEN
granted -
CA 3235923
PROCEDES DE SYNTHESE A GRANDE ECHELLE DE COMPLEXES DE RADIONUCLEIDES
granted -
CA 3240096
POLYTHERAPIE POUR LE TRAITEMENT DU CANCER DU POUMON
granted -
CA 3234495
POLYTHERAPIE DE COMPLEXE DE RADIONUCLEIDES
granted -
CA 3215723
PROCEDES DE DIAGNOSTIC DU CANCER DE LA PROSTATE
granted -
CA 3202908
ANTAGONISTE D'INTEGRINES ALPHA-V BETA-3 ET/OU ALPHA-V BETA-5 RADIOMARQUE DESTINE A ETRE UTILISE EN TANT QU'AGENT THERAGNOSTIQUE
granted -
US 2022072166
METHOD OF TREATMENT OF NEUROENDOCRINE TUMORS
granted -
WO 2022043557
MÉTHODE DE TRAITEMENT DE CANCERS EXPRIMANT LE PSMA
granted
Frequently asked questions
What is US patent 3144557?
CA 3144557 (LIGANDS D'ANTIGENE MEMBRANAIRE SPECIFIQUE DE LA PROSTATE (PSMA) ET LEURS UTILISATIONS) is held by ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT]. Status: granted. Granted Jan 7, 2021. Expires Jan 2, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.
Who owns CA 3144557?
ADVANCED ACCELERATOR APPLICATIONS ITALY SRL [IT] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does CA 3144557 expire?
Our index shows an expiration date of Jan 2, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.